{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:38:54Z","timestamp":1789227534052,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012832","name":"Okinaka Memorial Institute for Medical Research","doi-asserted-by":"publisher","award":["2020"],"award-info":[{"award-number":["2020"]}],"id":[{"id":"10.13039\/100012832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1245\/s10434-021-09974-0","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T19:15:34Z","timestamp":1619464534000},"page":"7663-7672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma"],"prefix":"10.1245","volume":"28","author":[{"given":"Junichi","family":"Shindoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"9974_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13411","volume":"49","author":"N Kokudo","year":"2019","unstructured":"Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109\u201313.","journal-title":"Hepatol Res"},{"key":"9974_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907\u201317.","journal-title":"Lancet"},{"key":"9974_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000346222","volume":"2","author":"J Shindoh","year":"2013","unstructured":"Shindoh J, Kaseb A, Vauthey JN. Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer. 2013;2:47\u201354.","journal-title":"Liver Cancer"},{"key":"9974_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"9974_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"9974_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"9974_CR7","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459\u201365.","journal-title":"Clin Cancer Res"},{"key":"9974_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"9974_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000506202","volume":"9","author":"R Matsuki","year":"2020","unstructured":"Matsuki R, Kawai K, Suzuki Y, et al. Pathological complete response in conversion hepatectomy induced by lenvatinib for advanced hepatocellular carcinoma. Liver Cancer. 2020;9:358\u201360.","journal-title":"Liver Cancer"},{"key":"9974_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s40792-020-01078-3","volume":"6","author":"Y Ohya","year":"2020","unstructured":"Ohya Y, Hayashida S, Tsuji A, et al. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy. Surg Case Rep. 2020;6:318.","journal-title":"Surg Case Rep"},{"key":"9974_CR11","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.21873\/anticanres.13768","volume":"39","author":"N Sato","year":"2019","unstructured":"Sato N, Beppu T, Kinoshita K, et al. Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy. Anticancer Res. 2019;39:5695\u2013701.","journal-title":"Anticancer Res"},{"key":"9974_CR12","doi-asserted-by":"publisher","first-page":"e22782","DOI":"10.1097\/MD.0000000000022782","volume":"99","author":"T Tomonari","year":"2020","unstructured":"Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports. Medicine (Baltimore). 2020;99:e22782.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"9974_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22\u201331.","journal-title":"Oncology"},{"key":"9974_CR14","unstructured":"National Cancer Institute, Division of Cancer Treated and Diagnosis. Cancer Therapy Evaluation Program. Adverse events\/CTCAE. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#-ctc_40."},{"key":"9974_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1872-034X.2010.00703.x","volume":"40","author":"Y Kawamura","year":"2010","unstructured":"Kawamura Y, Ikeda K, Hirakawa M, et al. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res. 2010;40:1006\u201314.","journal-title":"Hepatol Res"},{"key":"9974_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000505190","volume":"9","author":"Y Kawamura","year":"2020","unstructured":"Kawamura Y, Kobayashi M, Shindoh J, et al. Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma may be a useful new predictor of early response to lenvatinib and overall prognosis. Liver Cancer. 2020;9:275\u201392.","journal-title":"Liver Cancer"},{"key":"9974_CR17","volume-title":"The general rules for the clinical and pathological study of primary liver cancer","author":"Liver Cancer Study Group of Japan","year":"2008","unstructured":"Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 5th edn. Tokyo: Kanehara; 2008.","edition":"5"},{"key":"9974_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"9974_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"9974_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"9974_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282\u201396.","journal-title":"Lancet Oncol"},{"key":"9974_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/j.1478-3231.2010.02441.x","volume":"31","author":"S Irtan","year":"2011","unstructured":"Irtan S, Chopin-Laly X, Ronot M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int. 2011;31:740\u20133.","journal-title":"Liver Int"},{"key":"9974_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3748\/wjg.v17.i17.2255","volume":"17","author":"N Williet","year":"2011","unstructured":"Williet N, Dubreuil O, Boussaha T, et al. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World J Gastroenterol. 2011;17:2255\u20138.","journal-title":"World J Gastroenterol"},{"key":"9974_CR24","doi-asserted-by":"publisher","first-page":"791013","DOI":"10.4061\/2011\/791013","volume":"2011","author":"L Barbier","year":"2011","unstructured":"Barbier L, Muscari F, Le Guellec S, et al. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol. 2011;2011:791013.","journal-title":"Int J Hepatol"},{"key":"9974_CR25","first-page":"501","volume":"38","author":"T Yoshimoto","year":"2018","unstructured":"Yoshimoto T, Imura S, Morine Y, et al. The outcome of sorafenib therapy on unresectable hepatocellular carcinoma: experience of conversion and salvage hepatectomy. Anticancer Res. 2018;38:501\u20137.","journal-title":"Anticancer Res"},{"key":"9974_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2217\/pme-2018-0114","volume":"17","author":"A Bertacco","year":"2020","unstructured":"Bertacco A, Vitale A, Mescoli C, Cillo U. Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. Per Med. 2020;17:83\u20137.","journal-title":"Per Med"},{"key":"9974_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12328-015-0594-7","volume":"8","author":"T Kitajima","year":"2015","unstructured":"Kitajima T, Hatano E, Mitsunori Y, et al. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8:300\u20135.","journal-title":"Clin J Gastroenterol"},{"key":"9974_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.9738\/INTSURG-D-14-00133.1","volume":"100","author":"K Nakamura","year":"2015","unstructured":"Nakamura K, Beppu T, Hayashi H, et al. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. Int Surg. 2015;100:908\u201314.","journal-title":"Int Surg"},{"key":"9974_CR29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12328-019-01077-4","volume":"13","author":"K Takeda","year":"2020","unstructured":"Takeda K, Tsurumaru Y, Yamamoto Y, et al. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. Clin J Gastroenterol. 2020;13:428\u201333.","journal-title":"Clin J Gastroenterol"},{"key":"9974_CR30","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.21873\/anticanres.13710","volume":"39","author":"A Takahashi","year":"2019","unstructured":"Takahashi A, Moriguchi M, Seko Y, et al. Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma. Anticancer Res. 2019;39:5149\u201356.","journal-title":"Anticancer Res"},{"key":"9974_CR31","doi-asserted-by":"publisher","first-page":"e0231828","DOI":"10.1371\/journal.pone.0231828","volume":"15","author":"S Kirino","year":"2020","unstructured":"Kirino S, Tsuchiya K, Kurosaki M, et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One. 2020;15:e0231828.","journal-title":"PLoS One"},{"key":"9974_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers11111769","volume":"11","author":"R Sasaki","year":"2019","unstructured":"Sasaki R, Fukushima M, Haraguchi M, et al. Response to lenvatinib is associated with optimal relativedose intensity in hepatocellular carcinoma: experience in clinical settings. Cancers (Basel). 2019;11:1769.","journal-title":"Cancers (Basel)"},{"key":"9974_CR33","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","volume":"17","author":"R Adam","year":"2012","unstructured":"Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225\u201339.","journal-title":"Oncologist"},{"key":"9974_CR34","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677\u201383.","journal-title":"J Clin Oncol"},{"key":"9974_CR35","first-page":"161","volume":"36","author":"K Murata","year":"2010","unstructured":"Murata K, Suzuki H, Okano H, et al. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36:161\u201370.","journal-title":"Int J Oncol"},{"key":"9974_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000334454","volume":"81","author":"T Kuzuya","year":"2011","unstructured":"Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in alpha-fetoprotein, but not des-gamma-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:251\u20138.","journal-title":"Oncology"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09974-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09974-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09974-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:17:04Z","timestamp":1634329024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09974-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["9974"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09974-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Junichi Shindoh and Yusuke Kawamura receive honoraria from Eisai Pharmaceutical Co., Ltd. Yuta Kobayashi, Masahiro Kobayashi, Norio Akuta, Satoshi Okubo, Yoshiyuki Suzuki, and Masaji Hashimoto have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}